Trial Profile
Randomized trial of epoetin alfa in patients with advanced non-small cell carcinoma of the lung (EPO-CAN-20)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms EPO-CAN-20
- 02 Jul 2007 Status changed from in progress to discontinued.
- 14 Nov 2006 New trial record.